Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies

Alessandra Bartoli\textsuperscript{a,b}, Carmela Cursaro\textsuperscript{a}, and Pietro Andreone\textsuperscript{a,c}

Purpose of review
SARS-CoV2 is a \(\beta\)-coronavirus, isolated for the first time in Wuhan in December 2019. Bilateral interstitial pneumonia is the hallmark of this disease. Liver is the second viral target for frequency and AST and ALT elevation is a common finding. From February 2020, two different cholangiopathies have been reported in COVID-19 patients. The aim of this article is to review the cases so far described in order to share information and awareness about these new clinical entities.

Recent findings
SARS-CoV2 seems to trigger autoimmunity and two cases of primary biliary cholangitis (PBC) have been developed after viral infection while more than 30 patients have showed a rapidly progressing cholangiopathy with features of secondary sclerosing cholangitis (SSC). For what concerns SSC pathogenesis, a theory combining multiple hits is the most recognized.

Summary
Two different cholangiopathies have been reported in patients after severe-COVID-19. Attention should be paid to the development of cholestasis in ICU setting but above all after discharge and liver function tests should be, therefore, periodically performed. No treatment strategies are available and liver transplantation remains the last option in individuals with liver failure because of SSC. Other efforts are necessary to better understand the pathogenesis and to expand therapeutic options.

Keywords
cholangiopathy, coronavirus disease 2019, primary biliary cholangitis, secondary sclerosing cholangitis

INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a \(\beta\) coronavirus isolated for the first time in Wuhan, China in December 2019. Coronavirus disease 2019 (COVID-19) is characterized by fever, cough, anosmia, ageusia, sometimes diarrhoea, culminating in bilateral interstitial pneumonia followed, in some cases, by an abnormal activation of the immune system which, if not controlled, determines severe complications, such as acute respiratory distress syndrome (ARDS), heart failure, acute renal insufficiency, liver failure and death [1]. Liver is the second viral target for frequency and mild-moderate alteration in liver enzymes is often seen in hospitalized patients [2]. From SARS-CoV2 pandemic, two different diseases, both affecting the biliary tract, have been reported. The first one shows an autoimmune origin and has the features of primary biliary cholangitis (PBC) whereas the second displays the characteristics of a secondary sclerosing cholangitis and its pathogenesis is uncertain [3\textsuperscript{a},4,5]. In this review, we focused our attention on patients' common features, treatment received, imaging and histology findings in order to establish a disease profile and clarify the debated pathogenesis options.

LIVER DISEASE IN CORONAVIRUS DISEASE 2019
During COVID-19 hospitalization, a variable percentage of patients, ranging from 14 to 76\%, develops transaminase alterations with a greater
The pathogenesis of liver involvement in COVID-19 is unclear [18]. Interleukin 6 (IL-6) is thought to be the key point of endotheliopathy and coagulopathy, and some researchers have studied its influence in the development of COVID-19-related liver damage [19]. Through the trans-signalling pathway, IL-6 can interact with cells that are not representing its classical targets and among them, liver sinusoidal endothelial cells (LSECs) can be found. LSECs, stimulated by IL-6, produce higher amounts of procoagulant factors (von Willebrand factor and factor VIII), pro-inflammatory mediators (IL-6, chemokine C-X-C ligand 1–2) and adhesion molecules (intercellular adhesion molecule 1, P and E-selectin), which mediate platelet aggregation and attachment and neutrophils recruitment [19]. COVID-19-related intrahepatic microangiopathy seems to hit three different vascular compartments with hepatic artery endothelial swelling, portal vein phlebitis, and sinusoid obstruction syndrome [20]. Sinusoidal thrombosis is a sort of hallmark in severe COVID-19 liver histology, suggesting a possible direct viral action in the pathogenesis of the disease [5].

**POST CORONAVIRUS DISEASE 2019 CHOLANGIOPATHIES**

At the moment, two distinct diseases have been reported in literature. The occurrence of an autoimmune disease with the characteristics of primary biliary cholangitis and a large duct cholangiopathy resembling secondary sclerosing cholangitis [3,4,5].

**Severe acute respiratory syndrome coronavirus-2-induced primary biliary cholangitis**

SARS-CoV2 demonstrated to trigger autoimmunity, in fact, two cases of PBC developing after viral infection were described [3,21]. In the first case, a 47 years old woman who developed a Guillain–Barré syndrome during ICU stay, showed, after discharge, a severe elevation of gamma glutamyltranspeptidase (GGT) and alkaline phosphatase (ALP) without jaundice. At liver ultrasound and MRI no abnormalities were noticed but antinuclear antibodies (ANA) and antimitochondrial antibodies (AMA) were highly positive and the liver biopsy was compatible with the diagnosis of PBC [3].

The other case is that of a 57 years old man who, 1 month after a mild COVID-19 not requiring hospital admission, developed nausea, abdominal pain and vomiting accompanied by itch with AST, ALT and GGT elevation in concert with
Severe acute respiratory syndrome coronavirus-2-induced secondary sclerosing cholangitis

General features
From February 2020, other cases of a post-COVID-19 cholangiopathy, different from that previously reported, have been described. Up to now, more than 30 patients all around the world have developed a rapidly progressive cholangiopathy requiring, in some cases, orthotopic liver transplantation (OLT) [4,5,8*,9,16*,22–26]. Subjects’ common features were a severe COVID-19 bilateral interstitial pneumonia, ICU admission, acute hypoxemic respiratory insufficiency needing mechanical ventilation with positive-end expiratory pressure (PEEP) up to 10–15 mBar, prone-positioning, the administration of a mix of different drugs and in some cases, circulation support through pressor agents, extracorporeal membrane oxygenation (ECMO) and dialysis. Patients were for the major part men with an age range from 29 to 77 years, no preexisting liver disease, or at most liver steatosis, suffering from obesity, hypertension and diabetes. These subjects showed a moderate increase in AST and ALT, early, at hospital admission, which tended to normalize during hospital stay. During ICU stay or later, after ICU discharge, they presented an increase in ALP, GGT and total bilirubin often accompanied by jaundice. These alterations tended to augment despite cardiovascular and pulmonary recovery [4,5,8*,9,16*,22–26]. ALP and GGT often tended to reach values higher than 10 times ULN. Hepatotropic viruses and liver autoimmunity were negative [24,25].

Table 1 lists the main demographical and clinical features of described cases with peak values of transaminases and cholestasis indexes.

MRI and magnetic resonance cholangiopancreatography (MRCP) common findings were mild dilatations and strictures of intrahepatic bile ducts with ‘beaded’ appearance and biliary casts [4,8*,16*,23,24]. In many cases, alterations of the common bile duct, in form of dilatation were observed, not always accompanied by strictures [4,8*,24].

Some patients performed endoscopic retrograde cholangiopancreatography (ERCP) with papilla sphincterotomy and common bile duct stenting or balloon dilatation, without benefits even in case of biliary sludge and stone elimination [8*,22,25]. The vast majority of subjects, as last step, underwent liver biopsy and the main common findings consisted in portal and periportal fibrosis, bridging fibrosis, inflammatory infiltrate (leucocytes and rare times plasma cells) in portal tracts, degenerative cholangiocytes injury with cytoplasm vacuolization, regenerative changes and terminal bile ducts and marginal ductules cholangiocytes necrosis. Cytokeratin 7 immunostain positivity was observed in some biopsy samples, indicating ductular reaction. Other findings consisted in acute and/or chronic large duct obstruction and vascular damage, in particular, hepatic artery endothelial swelling, hepatic veins endophlebitis and in a case, focal features of sinusoidal obstruction syndrome [4,5,8*,16*,22,24].

The disease has thereby the features of a secondary sclerosing cholangitis.

MRI, MRCP, ERCP and biopsy findings of the reported cases are listed in Table 2.

Pathogenesis
Some authors related this disease to the use of ketamine as general anaesthetic for sedation during mechanical ventilation, in COVID ICUs [23]. Ketamine has been used during the pandemic as off-label second line agent and postketamine cholangiopathy is a known rare side effect [27,28]. Mallet et al. observed five patients developing a post-COVID-19 cholangiopathy after mechanical ventilation and sedation with ketamine. Liver injury seemed to be dose-dependent and progressive [23]. Bütikofer et al. compared 34 COVID-19-intubated patients with 34 influenza intubated patients. Four of 34 in the first group versus none from the second developed a severe cholangiopathy. Ketamine was used for sedation in the entire first group and for none from the second [26]. Ketamine in fact is metabolized in the liver through nitrogen demetilation to norketamine, a water-insoluble intermediate, which can precipitate in biliary ducts determining ductal structural alterations and consequently, cholestasis [23]. The drug may, therefore, represent a second hit on a liver already compromised by other factors [29].

Other authors have indeed associated post-COVID-19 cholangiopathy to secondary sclerosing cholangitis in critically ill patients (SSC-CIP) [4,5,8*,9,16*,22,24–26]. This is a rare complication affecting patients who have been long time hospitalized in the ICU for different causes, needing for mechanical ventilation [30]. SSC-CIP patients have neither history of prior liver disease nor hypergammaglobulinemia. AMA, antismoothmuscle antibodies and antidouble stranded DNA antibodies were positive and an autoimmune hepatitis overlapping with PBC was diagnosed [21].
Table 1. Patients’ general features with demographic data and information regarding treatments, mechanical ventilation duration, complications occurred during the acute phase of COVID-19 with cholestatic enzymes peak values and timing

| Reference | Number of subjects | Sex | Underlying conditions | Body mass index (BMI, Kg/m²) | Drugs administered during hospital stay | Mechanical ventilation (MV) duration (days) | Pressor agents | Sedation | Complications | GGT, ALP (U/L) and total bilirubin (TB, mg/dl) peak |
|-----------|--------------------|-----|-----------------------|---------------------------|--------------------------------------|---------------------------------|----------------|--------|-------------|-----------------------------------------|
| Malli V, et al. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021 May;74(5): 1243--1244 | 5 | M 60% F 40% | Range 35–65; median 59 | 3/5 hypertension, 2/5 diabetes, 1/5 kidney transplantation, 1/5 HBV infection in treatment with entecavir, 1/5 resolved hepatitis B | Range 21–33; median 28 | Not specified | Median 60 | 5/5 norepinephrine for 10 (2–13) days | 5/5 ketamine 5/5 acute kidney failure; 3/5 dialysis | AST and ALT elevation early after admission: GGT 30.7 × ULN, ALP 9.2 × ULN, TB 18 × ULN |
| Roth NC, et al. Post-COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol. 2021 May 1;116(5):1077--1082 | 3 | M 67% F 23% | Range 25–40; median 34 | 1/3 diabetes | Not reported | 3/3 hydroxychloroquine, 3/3 azithromycin, 1/3 levomethadione, 2/3 corticosteroids, 2/3 tocilizumab, 2/3 azithromycin, 1/3 concomitant diabetes, 1/3 renal disease, 3/3 antibiotics | Mural tractectomy until day 63 (2/3) and day 112 (1/3) | 3/3, drug not specified | 3/3 acute kidney failure, 2/3 dialysis; 1/3 ECMO; 2/3 biventricular systolic heart failure; 2/3 secondary infection; 1/3 cardiac arrest | AST and ALT elevation early after admission: GGT not reported, ALP 16 × ULN at day 139 (pt 1), 103 (pt 2), 172 (pt 3); TB 20 × ULN at day 181 (pt 1), 105 (pt 2) and 182 (pt 3) |
| Faruqui S, et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol. 2021 Jul 1;116(7):1414--1425 | 12 | M 92% F 8% | Range 38–73; median 58 | 9/12 hypertension, 5/12 diabetes, 5/12 obesity, 1/12 hepatic steatosis without cirrhosis, 3/12 cardiovascular disease, 6/12 type 2 DM | Not reported | 7/12 hydroxychloroquine, 10/12 azithromycin, 2/12 tocilizumab, 2/12 remdesivir, 8/12 corticosteroids, 4/12 heparin prophylaxis, 1/12 azithromycin, 1/12 dexamethasone | Median 60, range 13–138 | 10/12, drug not specified | 12/12 adipsia, 8/12 thrombosis, 3/12 ECMO, 8/12 paronaria | AST and ALT elevation early after admission: GGT not reported, ALP 10 × ULN and TB 35 × ULN. Days from COVID-19 diagnosis to cholangiopathy discovery: 117.7 ± 18 |
| Durazzo RA, Nicholas AA, et al. Post-Covid-19 Cholangiopathy: A New Indication for Liver Transplantation. A Case Report. Transplant Proc. 2021 May;53(5):1132–1137 | 1 | M 47 | None | 51 | Severe obesity, obstructive sleep apnoea, hypertension, hyperlipidaemia, no history of liver disease | Hydroxychloroquine, azithromycin and high dose vitamin C | Not reported | Not reported | Acute kidney injury, ECMO and dialysis (30 months) | AST and ALT elevation early after admission: GGT not reported, ALP 1 644 U/L, TB 19 mg/dl. Chemistry peak was registered at day 58 from hospital admission |
| Tafreshi S, et al. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging. 2021 Jul 27;80:239–242 | 1 | M 38 | None | Not reported | Hydroxychloroquine, azithromycin, tocilizumab | Not reported | Not reported | Not reported | Acute kidney failure, ECMO; dialysis and embolic stroke | AST and ALT elevation early after admission: GGT not reported, ALP 3665 U/L, TB 9.8 mg/dl. Peak registered at a few months from hospital admission |
| Reference                  | Number of subjects | Sex | Age (years) | Underlying conditions                                                                 | Body mass index (BMI, Kg/m²) | Drugs administered during hospital stay                                                                 | Mechanical ventilation (MV) duration (days) | Pressor agents | Sedation | Complications                                                                                           | GGT, ALP (U/L) and total bilirubin (TB, mg/dl) peak |
|---------------------------|--------------------|-----|-------------|---------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------|----------------|----------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Lee A, et al. Liver       | 1 M 64             |     | 29.8        | Hypertension, hyperlipaemia, diabetes and radical prostatectomy for cancer              |                             | Hydroxychloroquine, azithromycin, tocolizumab, convalescent plasma, furosemide and anticoagulants               | 14                                          | Not reported   | Not reported | Bilateral limbs deep venous thrombosis and consequent inferior vena cava filter placement; line-related candidemia | AST and ALT elevation early after admission. AIP and TB peak at day 24 after admission; audiocese at day 51 after admission |
| Klindt C, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature. Clin Case Rep. 2021 May 24;9(5): e04068 | 1 M 47             |     |             | None                                                                                   | Not reported                 | Lopinavir/ritonavir, remdesivir, piperacillin/tazobactam, clarithromycin and meropenem                       | Not reported                                    | 2 days, drug not specified | Not reported | AST and ALT elevation early after admission. GGT, AIP and TB gradually increased from admission with GGT (28.6 ± ULN) and AIP (9.91 ± ULN) peak at day 51 and TB (21.63 ± ULN) peak at day 144 | GGT (28.6 ± ULN) and AIP (9.91 ± ULN) peak at day 51 and TB (21.63 ± ULN) peak at day 144 |
| Rojas M, et al. Cholangiopathy as part of postCOVID syndrome. J Transl Autoimmun. 2021;4: 100116 | 1 F 29             |     |             | Obesity                                                                                | Not reported                 | Antibiotics, colchicine, enoxaparin, aspirin, dexamethasone and furosemide                                   | Not reported                                    | Not reported   | Not reported | Acute kidney injury, troponin elevation and sepsis                                                                 | After 2 months from admission, jaundice and AST, AIP and TB elevation |

AST, alanine aminotransferase; AIP, alkaline phosphatase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 19; ECMO, extracorporeal membrane oxygenation; GGT, gamma glutamyl transpeptidase; Nr, number; pts, patients; TB, total bilirubin; ULN, upper limit normal.
| Reference | CT/MRI/MRCP | ERCP | Biopsy | Prognosis |
|-----------|-------------|------|--------|-----------|
| Mallet V, et al. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021 May;74(5):1243-1244 | Strictures and dilatation of intrahepatic bile ducts, biliary casts and peribiliary cysts | One of three filling defects in common bile duct and depletion of intrahepatic bile ducts. One biliary cast removed | Two of five: severe biliary cirrhosis and fibrosis; 4/5: cholangio-proliferation, biliary plugs and portal inflammation with leucocyte infiltrate. | Two of five died for decompensated cirrhosis and biliary sepsis. Three of five survived: 1/5 pruritus and 2/5 recurrent biliary sepsis. |
| Roth NC, et al. Post-COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol 2021 May 1;116(5):1077--1082. | Two of three hepatomegaly, 1/3 extrahepatic bile ducts dilatation and 1/3 intrahepatic bile ducts strictures and dilatations with beaded aspect or solely dilatation | Two of three: sphincterotomy with stones and sludge expulsion but no clinical benefits | Two of three mild and moderate bile ducts paucity; 3/3 moderate ductular reaction; 3/3 cholangio-cytes swelling and regenerative changes with portal tract inflammation; 3/3 hepatic artery endothelial swelling, hepatic veins endophlebitis and 1/3 focal features of sinusoidal obstruction syndrome. 1/3 bridging portal fibrosis and 3/3 perportal fibrosis | Three of three still alive, 2/3 discharged home, 1/3 still hospitalized. Clinical conditions not specified |
| Faruqui S, et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol 2021 Jul 1;116(7):1414-1425 | Eleven of twelve beaded images of intrahepatic bile ducts, 7/12 bile ducts thickening and hyperenhancement, 10/12 peribiliary diffusion high signal | Three of twelve papilla sphincterotomy and stenting of the common bile duct (CBD), balloon dilatation of strictures in left and right hepatic ducts without clinical benefits. Multiple strictures in intrahepatic bile ducts observed | Performed in four of twelve pts. Acute or chronic large bile ducts obstruction, mild fibrosis of some portal tracts, Keratin 7 immunostain positivity | Four of twelve died for complications consequent to sclerosing cholangiopathy. 1/12 rejected from transplantation program because of old age and multiorgan failure (last TB 3.5 mg/dl), 2/12 listed for transplantation, 1/12 LT from a living donor, 4/12 not listed for LT and take UDCA. UDCA slightly improved some lab tests (AST and ALT) but GGT and ALP remained elevated |
| Durazo FA, Nicholas AA, et al. Post-Covid-19 Cholangiopathy—A New Indication for Liver Transplantation: A Case Report. Transplant Proc 2021 May;53(4):132-1137 | Mild intrahepatic bile ducts dilatation with focal strictures and beaded aspect, no dilatation of CBD | Sphincterotomy and a small stone extraction without clinical benefits. Intrahepatic ducts with short segmental strictures and dilatations | Inflammatory mononuclear infiltrates of bile duct walls with increased collagen deposition, liver abscesses and bile lakes. Endothelial cell swelling, lumen obliteration of arterial vessels and oblitative portal venopathy | At day 108 from hospital admission, orthotopic liver transplantation (OLT). Seven months after LT, normal liver function, normal ALP and TB. |
| Tafreshi S, et al. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging 2021 Jul 27;80:239-242 | Mild dilatation of intrahepatic bile ducts with beaded aspect, dilatation of CBD and periporal oedema | Attenuated and sinuous intrahepatic bile ducts with normal extrahepatic ducts | Cholangioocytes injury, ductular proliferation, canalicular cholestasis, a bile lake and focal bridging fibrosis | Under evaluation for LT |
| Reference                  | CT/MRI/MRCP                                                                 | ERCP                                                                 | Biopsy                                                                 | Prognosis                                                                 |
|----------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Lee A, et al. Liver transplantation for post-COVID-19 sclerosing cholangitis BMJ Case Rep 2021 Aug 26;14(8):e244168. | CBD dilatation, mild intrahepatic bile ducts dilatation and diffuse biliary hamartomas | Ductopenia of the left and right ducts with beaded appearance; filling defect suggesting biliary casts | Explant pathology: bridging fibrosis, severe biliary duct injury, ductular reaction and leucocytes and plasma cells infiltrate | LT after 259 days from COVID-19 hospital admission. Eight months after LT, the liver function and cholestasis indexes are in range |
| Klindt C, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature. Clin Case Rep 2021 May 24;9(5):e04068 | Alterations of medium and small intrahepatic bile ducts | Not performed | Enlarged portal tracts with phlogistic infiltrate, ductular reaction with degenerative alterations of bile duct epithelium, focal biliary metaplasia of perportal hepatocytes. A few bile infarcts and perivenular canalicular cholestasis | LT |
| Rojas M, et al. Cholangiopathy as part of post-COVID syndrome. J Transl Autoimmun 2021;4:1001-16 | Only a cystic lesion in liver segment VII | Negative for any alteration | Low periportal phlogistic infiltrate without necrosis but with a severe obstructive cholestatic pattern | UDCA and cholestyramine were administered and just a slightly improvement was observed. Even if the autoimmunity profile panel was negative, the authors think these tests should be repeated without the hyper bilirubin confounding factor. This case is different from the other ones described above. |

ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CBD, common bile duct; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; GGT, gamma glutamyl transpeptidase; LT, liver transplantation; MV, mechanical ventilation; MRCP, magnetic resonance cholangiopancreatography; OLT, orthotopic liver transplantation; pts, patients; TB, total bilirubin; UDCA, ursodeoxycholic acid; UNL, upper limit normal.
cholangiopathy and even if the pathogenesis is uncertain, hypoxemia of the hepatosplanchnic district may represent the leading cause, in particular, due to systemic hypotension for prolonged time [31]. Mechanical ventilation with PEEP higher than 10 cm H2O can determine microcirculatory ischemia of the splanchnic plexus [32]. The prone position for long time during mechanical ventilation and the administration of pressor agents as norepinephrine, epinephrine and dobutamine can also decrease the hepatosplanchnic blood-flow [33]. SSC-CIP mortality reaches high rates and is up to 50% during ICU stay [34]. In a study, 60% of affected patients survived; 20% needed OLT and the remaining developed a biliary cirrhosis [35]. Precipitating factors are concomitant renal failure, a rapid deterioration of liver function with liver insufficiency and cirrhosis and a high model for end-stage liver disease (MELD) score [34]. Without OLT, the average survival is 12–44 months [36]. Even if similarities among the two clinical entities are evident, histology seems to differ; biopsies performed in post-COVID-19 cholangiopathy showed diffuse degenerative cholangiocyte lesions with extreme cytoplasm vacuolization and regenerative change, never mentioned in SCC-CIP [5]. For what concerns post-COVID-19 secondary sclerosing cholangitis, a theory combining multiple hits or the combination of SSC-CIP with direct viral damage are the most accepted [4,5,8*,22].

The hypoxic factor, as described above, can also be applied to post-COVID-19 cholangiopathy [37]. Moreover, as SARS-CoV2 severe infection is associated with blood hypercoagulability and thrombosis, hypoxia of the hepatosplanchnic district could be worsened [38]. Cholangiocytes are more sensitive than hepatocytes to ischaemia because of their specific vascularization. In case of local ischaemia, biliary epithelium develops necrosis and sloughing with consequent bile casts production and bile ducts structural alterations [31].

Another debated co-factor consists in drug-induced live injury (DILI) [39]. COVID-19 severe patients are, in fact, administered with different drugs mix. Hydroxychloroquine, azithromycin, remdesivir, lopinavir/ritonavir, tocilizumab, corticosteroids, anti-fungal drugs and antibiotics were the medications most frequently given [4,5,8*,16*, 22,24,25]. DILI is a diffuse phenomenon that can be caused by direct cytotoxicity or idiosyncratic reactions and sclerosing cholangitis-like diseases have been reported in literature [39]. None of the above cited drugs is known to cause cholangiopathies [40].

A third hit may be represented by the hyper-activation of the immune system leading to the ‘cytokine storm’. The most important mediators of this complication are pro-inflammatory cytokines, such as IL-1, IL-6 and TNF-α, with IL-6 being considered as key point in endotheliopathy and inflammation in COVID-19 disease. Inflammation-mediated SSC has been reported in some auto-inflammatory diseases [18,41].

The last causative factor could be represented by SARS-CoV2 direct cytopathic effect as cholangiocytes are known to express large amounts of ACE-2 receptors. The alteration of normal functioning and homeostasis of cholangiocytes because of multiple factors (ischaemia but also hyperinflammatory environment and direct viral effect) may lead to the subversion of self-protective cell mechanisms and toxic bile damage. In order to protect themselves from bile acid aggression, cholangiocytes secrete bicarbonates whereas hepatocytes secrete phospholipids. An alteration of this secretory equilibrium may cause biliary epithelium damage and consequent biliary ducts sclerosis and SSC development [31].

Treatment and prognosis
In the reported cases, ursodeoxycholic acid and cholestyramine were of modest benefit on pruritus and did not arrest disease progression.

Prognosis remained severe, requiring liver transplantation in many patients [24,26]. In a case series of 12 patients, 4 of 12 died, 5 of 12 were listed for OLT, 1 of 12 was rejected from OLT list because of ineligibility. Six of 12 patients repeated MRI after 6 months from the first one and 4 of 6 showed a rapid disease progression [8*]. Even if only some case reports are available, the transplanted patients showed on average a good survival rate with complete recovery of liver function and wellness lasting at least 6–8 months after OLT [5,24,42].

CONCLUSION
SARS-CoV2 is a newly discovered virus and little is known about its direct cytopathic and indirect effects, including disruptive potentials on human immune system. These cholangiopathies represent an open issue in science world as their causative factors are far from being explained and understood. PBC has been related to viral infections acting as triggers, determining autoimmune activation with consequent biliary ductal lesions and cholestasis; for what concerns SSC, its pathogenesis is more uncertain and complex, leading to a severe and rapidly progressing disease.

The two cholangiopathies are sustained by different mechanisms and even if until now a few cases
have been reported, they should be kept into account. Blood tests constituting AST, ALT, ALP, GGT and total bilirubin should be periodically performed during ICU stay and above all after discharge, in order to promptly detect any alteration. Other studies are necessary to understand the exact pathogenesis of these diseases and to develop new therapeutic strategies.

Acknowledgements
None.

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
■ of special interest
■■ of outstanding interest

1. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7:11.
2. Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol 2020; 73:566–574.
3. Bartoli A, Gatto S, Sighinolfi P, et al. Primary biliary cholangiitis associated with SARS-CoV-2 infection. J Hepatol 2021; 74:1245–1246.
4. Tafreshi S, Whiteside I, Levine I, D’Agostino C. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging 2021; 80:239–242.
5. Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-COVID cholangiopathy-a new indication for liver transplantation: a case report. Transplant Proc 2021; 53:1132–1137.
6. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020; 72:287–304.
7. Sulton S, Altayar O, Siddique SM, et al. AGA Institute. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020; 159:320. e27-334.e27.
8. Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol 2021; 116:1414–1425.
9. Complete and exhaustive review about post COVID-19 secondary cholangiopathy, discussing histology, pathogenesis and patients’ clinical features.
10. Neesessaman P, Blondeel J, De Weger G, et al. Collaborators Leuven Liver Transplant program. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med 2021; 47:1037–1040.
11. Hundt MA, Deng Y, Carlegio MM, et al. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a Major U.S. Hospital Network. Hepatology 2020; 72:1169–1176.
12. Ye Q, Wang B, Zhang T, et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol 2020; 3;21-4255–G252.
13. Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organs. Protein Cell 2020; 11:771–775.
14. Moreira JS, Barbosa SMB, Gonçalves Junior J. Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. Clin Res Hepatol Gastroenterol 2021; 45:101752.
15. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID-19 respiratory failure is suggestive of vascular alterations. Liver Int 2020; 40:2110–2116.
16. The article suggests interesting perspectives in COVID-19 pathogenesis.
17. Kalschmidt B, Fitzek ADE, Schaedler J, et al. Hepatic vasculopathy and regenerative responses of the liver in fatal cases of COVID-19. Clin Gastroenterol Hepatol 2021; 19:1729–e27.
18. The article suggests interesting perspectives in COVID-19 pathogenesis.
19. Klintz C, Jensen BE, Brandenburger T, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: a case report and review of the literature. Clin Case Rep 2021; 9:e04688.
20. Insights about post COVID-19 secondary sclerosing cholangitis.
21. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020; 73:807–816.
22. Gupta A, Madhavan MV, Sehgal K, et al. Extrapoliminary manifestations of COVID-19. Nat Med 2020; 26:1017–1032.
23. McConnell MJ, Kawaguchi N, Kondo R, et al. Liverinjury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol 2021; 75:647–658.
24. Interesting study about COVID-19 vascular damage pathogenesis.
25. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 2020; 33:2147–2155.
26. Singh B, Kaur P, Maroules M. Autimmune hepatitis-primary biliary cholangitis overlap syndrome triggered by COVID-19. Eur J Case Rep Intern Med 2021; 8:002264.
27. Rith NC, Kim A, Vikovski T, et al. Post-COVID cholangiopathy: a novel entity. Am J Gastroenterol 2021; 116:1077–1082.
28. Keta-Cov research group. Electronic address: vincent.mallet@aphp.fr, Keta- Cov research group. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol 2021; 74:1243–1244.
29. Lee A, Wein AN, Doyle MBM, Chapman WC. Liver transplantation for post-COVID-19 sclerosing cholangiopathy. BMJ Case Rep 2021; 14:e204418.
30. Rojas M, Rodriguez Y, Zapata E, et al. Cholangiopathy as part of post-COVID syndrome. J Transl Autoimmun 2021; 4:100116.
31. Bülkiker S, Lengeberger D, Wendel Garcia FD, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int 2021; 41:2404–2417.
32. Changues G, Constantin JM, Devlin JW, et al. Analgesia and sedation in patients with ARDS. Intensive Care Med 2020; 46:2342–2356.
33. Agence nationale de sécurité du medicament et de produits de sante (ANSM). Ketamine: risk of serious liver damage during prolonged use and/or at high doses-Information Point. June 20, 2017. Available at: https://ansm.sante.fr/S-informer/Points-d-information/Points-d-information/Ketamine-ris- que-d-atteintes-hepatiques-graves-lors-d-utilisations-prolongees-et-eu-a-doses-elevees-Point-d-Information. [Accessed date 20 Sept 2020].
34. de Tymowski C, Depret F, Dudoignon E, et al. Ketamine-induced cholangiopathy in ARDS patients. Intensive Care Med 2021; 47:1173–1174.
35. Esposito I, Kubaisa A, Steihl A, et al. Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis. Virchows Arch 2008; 453:339–345.
36. Leonhardt S, Vetelko-Schilker W, Adler A, et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care 2015; 19:131.
37. Kirchner GL, Rümmele P, Update on Sclerosing Cholangitis in Critically Ill Patients. Vizzeramedizin 2015; 31:178–184.
38. Meier-Hellmann A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997; 25:399–404.
39. Voigtlander T, Negm AA, Schneider AS, et al. Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome. Endoscopy 2012; 44:1056–1058.
40. Li T, Qu K, Xu X, et al. Sclerosing cholangitis in critically ill patients: an important and easily ignored problem based on a German experience. Front Med 2014; 8:118–126.
41. Kulakos H, Heuberger D, Engler S, Steihl A. Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 2008; 40:214–218.
42. Grasselli G, Zaninotto A, Zanella A, et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323:1574–1581.
43. Conrons MM, Levy JH. Thrombininflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020; 18:1559–1561.
44. Chen M, Suzuki A, Börak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 2015; 63:503–514.
45. Oty A, Meunier L, Deire B, et al. Drug-induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf 2020; 43:615–617.
46. Erkelens GW, Vleggaar PP, Lestershus W, et al. Sclerosing pancreatocho- langitis responsive to steroid therapy. Lancet 1989; 354:34–44.
47. Bethuneid LD, Suven TK, Post COVID-19 cholangiopathy - adepo dive. Dig Liver Dis 2021; 53:1235–1236.